Ligand Pharmaceuticals Incorporated (LGND) : The total money flow in Ligand Pharmaceuticals Incorporated (LGND) was negative ($2.06 million), showing the domination of sellers in the Monday trading session. The traders utilized every rise to sell their positions, as seen in the value of trading on downtick to the tune of $5.18 million. Transactions on upticks were comparatively lower at $3.12 million. The uptick to downtick ratio was 0.6. The total block trades on downticks were valued at $2.21 million. The money flow during block trades was negative ($2.21 million) when the stock traded with a gain of $9 cent. Ligand Pharmaceuticals Incorporated (LGND) was $126.12, an increase of 0.07% over the previous days close.
Ligand Pharmaceuticals Incorporated has dropped 0.27% during the last 3-month period . Year-to-Date the stock performance stands at 16.21%. Ligand Pharmaceuticals Incorporated has dropped 0.6% in the last five trading days, however, the shares have posted positive gains of 8.86% in the last 4 weeks. In a related news, The director, of Ligand Pharmaceuticals Inc, Kozarich John W had unloaded 1,000 shares at $121.08 per share in a transaction on July 1, 2016. The total value of transaction was $121,080. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): On Mondays trading session , Opening price of the stock was $124.95 with an intraday high of $126.38. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $124.77. However, the stock managed to close at $126, a loss of 0.02% for the day. On the previous day, the stock had closed at $126.03. The total traded volume of the day was 267,330 shares.
Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them with a lean corporate cost structure. The Companys technology CAPTISOL is a formulation technology that has enabled seven United States Food and Drug Administration (FDA) approved products including Kyprolis and Noxafil-IV and is being developed in several clinical-stage partner programs. The Company is engaged in the development of product candidates indicated for the treatment of diseases, such as hepatitis, multiple myeloma, muscle wasting, Alzheimers disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis (FSGS) and osteoporosis.